Evidence map›Paper›PMID 40496804›Full record

ArticlePhysics and imaging in radiation oncology2025

Prediction of Grade 4 radiation-induced lymphopenia during chemoradiation therapy for lung cancer patients: Insights from two past trials.

Serena Monti, Giuseppe Palma, Ting Xu, Radhe Mohan, Zhongxing Liao, Laura Cella

2 registry-linked trialsAbstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00533949 phase3completednot on this map

A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer

TypeinterventionalSponsorRadiation Therapy Oncology GroupRan2007 to 2022Enrolled544ConditionsLung Cancer, Radiation ToxicityArmsCetuximab, Carboplatin, Paclitaxel, 60 Gy RT, 74 Gy RT
NCT00915005 phase2completednot on this map

A Bayesian Randomized Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2009 to 2020Enrolled275ConditionsNon-Small-Cell Lung CarcinomaArmsPhoton Therapy, Proton Therapy, Paclitaxel, Carboplatin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Serena MontiNational Research Council, Institute of Biostructures and Bioimaging, Napoli, Italy.
Giuseppe PalmaNational Research Council, Institute of Nanotechnology, Lecce, Italy.
Ting XuThe University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Houston, USA.
Radhe MohanThe University of Texas MD Anderson Cancer Center, Department of Radiation Physics, Houston, USA.
Zhongxing LiaoThe University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Houston, USA.
Laura CellaNational Research Council, Institute of Biostructures and Bioimaging, Napoli, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: Radiation-induced lymphopenia (RIL) is a significant side effect associated with radiation therapy (RT) with important prognostic implications. We developed and tested a normal tissue complication probability (NTCP) model for Grade 4 (G4) RIL in patients with locally advanced Non-Small-Cell Lung Cancer (NSCLC) who underwent concurrent chemotherapy and RT, analyzing data from patients enrolled in two clinical trials. Materials and Methods: We retrospectively analyzed the data from NCT00915005 (MDA-cohort) and NCT00533949 (RTOG0617-cohort) trials. After finding the candidate predictors of G4-RIL, defined as absolute lymphocyte count (ALC) at nadir < 0.2*10 Results: In the MDA-cohort, 55 out of 161 (34%) patients developed G4-RIL, while in the RTOG-cohort 16 out of 227 (7%) developed this condition. The relative volume of healthy lungs receiving at least 5 Gy (V Conclusions: Baseline ALC and lung V

Identifiers

PMID40496804
PMCPMC12151671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.